February 3rd 2023
The rate of adverse events was lower in the combination group than it was in patients in the guselkumab or golimumab monotherapy groups at week 50.
February 2nd 2023
Abbott Announces Regulatory Decisions for a Pair of Arrhythmia Devices
February 2nd 2023On February 2, Abbott announced their FlexAbility™ Ablation Catheter, Sensor Enabled had received an expanded approval from the US Food and Drug Administration and their TactiFlex™ Ablation Catheter, Sensor Enabled received a CE Mark.
New Data Show Severe Maternal Morbidity is a Threat to People with Sickle Cell Disease
February 2nd 2023"Despite advances in SCD management and high-risk pregnancy care, at the national level, outcomes in this population have not improved since the last NIS analysis of data from 1999 to 2008," investigators write.
Gluconic Acid Could Serve as Race-Specific Biomarker for Hypertension and Stroke Risk
February 2nd 2023A study presented at the International Stroke Conference 2023 suggests the plasma metabolite gluconic acid could serve as a race-specific biomarker for identifying increased risk of hypertension and stroke in Black adults.
Daprodustat Receives FDA Approval for Anemia Caused by CKD on Dialysis
February 1st 2023Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.
Infliximab Biosimilar Competition did not Improve Affordability for Patients
Investigators evaluated whether the availability of the biosimilar infliximab was linked to lower out-of-pocket costs using claims from the IBM MarketScan national data set of commercially insured patients.
Transplant-Acquired Atopy and Allergy Found to be More Common in Pediatric Liver Transplants
New research into risk factors for pediatric liver transplant patients indicated that atopy and allergy may follow a transplant and are more common among females and younger patients.